- Email: [email protected]
Subject index to volume 27
1350
BIOLPSYCHIATRY 1990;27:1350-1365
Subject Index to Volume 27 Abnormal Involuntary Movement Scale scores on in chronic schizophrenia, 150 Acetylcholine in Alzheimer's disease, 1133 Acetylcholinesterase in Alzheimer's disease, depletion of, 373 levels, quantitative analysis of, 87 l ACTH. See Adrenocorticotropic hormone Adenylate cyclase in posttraumatic stress disorder, 735 Adolescents rapid cycling in, after antidepressant therapy, 1184-1e
ct2-Adrenergic receptors in bulimia nervosa, 5 in obsessive-compulsive disorder, 1083 {3-Adrenergic receptors in bulimia nervosa, 5 disorders of decision modulated by, 813 Adrenocorticotropic hormone (ACTH) adrenal response to, in depression, 930 circadian rhythm, in eating disorders, 1007 CRH-induced release of, 1094 CSF, in nervous and normal pointer dogs, 791 hy~rsecretion, limbic-hypothalamic overdrive~ induced, 160 in Parkinson's disease, after DST, 581 Affective disorders abnorma!~ties in daily rhythm of body temperature in, 39 antithyroid antibodies in, 51 DNA marker studies of, 241 familial, high prevalence of among nondepressed bulimics, 454 fragile X syndrome role in, 223 hypercortisolism in, 937 hypersomnia in, 372de noradrenergic/cholinergic imbalance theory of, 109 vitamin B~2 and folate effect on, 125 Aging circadian rest-activity rhythm alterations in, 563
Abbreviation ed: .F.ditonai le: Letter to the Edi:or © 1990 3ocieiy of Biological Psychiatry
CNS serotonergic responsivity and, 1143 increasing, as risk factor for cardiovascular disease, 99 reduction in natural killer cell cytotoxicity not associated with, 22 symptom severity in depression and, 311 AIDS. See Autoimmunodeficiency syndrome Akathisia chronic, rhythmic movements of, 465-1e beta-blockers against, 673-1e lorazepam and anticholinergics in, 463-1e sulcal size and, 466-1e ~-tryptophan in, 671-1e Alcohol consumption of, reduction in natural killer cell cytotoxicity not associated with, 22 Alcoholism CSF galanin levels in, 923 in depression, 231,478 family history of, 631,905, 1305 in monozygotic twins, heritability of, 1293 platelet MAd activity in, 91 ! pure primary, sleep patterns during withdrawal from, 477 reduced plasma GABA-like activity as biological marker for vulnerability to, 617 TSH and prolactin response to TRH in, 31 withdrawal from, age-related increase in plasma MHPG levels after, 626 Aluminum fluoride, plus sodium chloride, adenylate cyclase activity stimulated by, 735 tissue concentrations of, 884 AIzheimer's disease acetylcholinesterase in, 573 aluminum tissue concentrations in, 884 calcium channel blockers against, 1133 circadian rest-activity rhythm alterations in, 563 hypereortisolism in, 937 red cell folate and, 126 RS 86 against, 109 Amenorrhea in bulimia nervosa, noradrenergic disturbances associated with, 4 Amino acids precursors to, noradrenergic disturbances and, 4 Aminoacidopathies 0006-3223/90/$03.50
Subject Index to Volume 27
heterozygosity for more than on,~ of the loci for, 69 Amnesia vasopressin against, 289 Amphetamine sensory gating diminished by, 183 Amygdala dopamine concentration in, 1038 Anemia in geriatric psychiatric p~tic~t$, 125 Anerg~a antithyroid antibodies associated with, 52 physostigmine-induced, 109 Angiostensin-converting enzyme inhibitors antidepressant properties of, 968 Anorexia nervosa acute phase, GHRH-induced GH release lost in, 215 bulimia nervosa r~ore prevalent than, 4 cognitive performance in, 549 CRH-induced, 1094 growth hormone response to TRH in, 1227 hormonal circadian rhythms in, 1007 hypercortisolism in, 937 restraint stressDinduced, 1094 Anticardiolipin antibodies in chronic mental disorders, 747 neuroleptic-associated, 863 Anticholinergics against tardive ak2~hisia, 463-1e Anticonvulsant effec',s of ECT, 1282 Antidepressants against bufimia nervosa, 5 CRF interaction with, 953 rapid cycling upon withdrawal of, 1184-1e Antinuclear antibodies in chronic mental disorders, 747 neuroleptic-associated, prevalence of, 863 Antiphospholipid antibodies neuroleptic-associated, prevalence of, 863 Anti-Ro(SSA) antibodies in chronic mental disorders, 747 Anti-Ro(SSA)/anti-La(SSB) antibodies in chronic mental disorders, 747 Antiseptal autoantibodies in schizophrenia, 68 l-le, 68 I-le (response) Antisocial behavior in monozygotic twins, heritability of, 1293 Antithyroglobulin, frequency of in psychiatric patients, 5 ! Antithyroid antibodies frequency of in psychiatric disorders, 51
BIOLPSYCHIATRY 1990;27:1350-1365
1351
Antiviral activity of psychotropic medications, 447 Anxiety disorders cardiovascular disease risk and, 99 limbic seizures and, 249 (comment) TRH effect on blood pressure and heart rate in, 781 Anxiolytic drugs CRF interaction with, 953 Appetite in bulimia nervosa, disturbance of modulation of, 5 Arecoline REM induction test, in atypical depression, 441 Arginine vasopressin in psychiatric disorders, 1249 Arteritis antibodies in, 863 Ascorbic acid CSF concentration gradients of, 89 I Attention deficits in schizophrenic childre,, event-related potential correlates of, 1103 Auditory-evoked r~sponse brainstem, with and without sedation, 834 impaired, catecholamine metabolite levels and, 519 lithium effect on in healthy subjects, 555 in schizophrenia, 1216 Auditory hallucinations generation of, 81 i-ed humming-induced reduction of, 934-1e Autism brainstem auditory-evoked response in, with and without sedation, 834 fragile X syndrome role in, 223 Autoantibodies in chronic mental disorders, 747 Autoimmunity thyroid, as cause of hypothyroidism and hyperthyroidism, 51 Autoimmunodeficiency syndrome (AIDS) antibodies in, 863 Autosomal dominant gene single inherited, in obsessive-compulsive disorder and Tourette's syndrome, 95 Autosomal recessive disorders enzymatic activities in heterozygotes for, 69 Barbiturates in dogs, 1264 Basal ganglia calcification, in schizophrenia, 682-1e
1352
BIOLPSYCHIATRY
Subject Index to Volume 27
1990;27:1350- i 365
mineralization of, 138, 143 Bay-e-9736 calcium channel blocker against Alzheimer's disease, 1133 Benzodiazepine/GABA/chloride ionophore chloride ion involved in modulation of inhibitory neurotransmission through, 105 Benzodiazepines in dogs, 1264 against tardive akathisia, 463-Ie Beta-hydroxybutyric acid (BHBA) in bulimia, 1021 BHBA. See Beta-hydroxybutydc acid Bingeing plasma norepinephrine levels and, 4 Bipolar affective disorder antithyroid antibodies in, 51 brain TI levels in, 116 cell membrane affinity for lithium ion during, 795 circadian temperature rhythms in, 40 familial, linkage analysis of, 241 iron pigment deposition in, 139 MRI of cerebral structures in, ! 188 psychosurgery against, 363 treatment of, 1045 ventricular enlargement and, 341 Birth season of, electrodermai unresponsiveness in schizophrenia correlated to, 328 Blinking in schizophrenia, ! 13, ! 197 Blood pressure in anxiety disorders, TRH effect on, 781 clonidine effect on, 1083 in posttraumatic stress disorder, ! 165 Blood-brain barrier RS 86 passage through, 109 Body image in bulimia nervosa, disturbance of, 5 Brain interaction between immune system and, during psychological stress, l-ed Brainstem auditory-evoked response, with and without sedfition, 834 Bulimia nervosa brain T! levels in, 116 cognitive performance in, 549 growth hormone response to TRH in, 1227 normal weight, noradrenergic disturbaces in, 4 sleep patterns and dexamethasone suppression in, 454
Buspirone CRF interaction with, 953 CA1 neurones rat hippocampus, lithium effect on synaptic transmissions in, 174 Calcium chan~el blockers, against Alzheimer's disease, 1133
plasma concentrations of, lactate-induced panic attacks and, 104 Camphor in convulsive therapy, 76 (comment) Cap:opril amidepressant properties of, 968 against self-induced water intoxication, 787 Carbamazepine against multiple personality disorder, 1045 Carbon dioxide five percent challenge, in panic disorder, 689 Cardiovascular disease risk factors for in psychiatric patients, 99 Cata#exy in narcolepsy, 1057 Catatonia presence of minerals correlated with, 138 Catecholamines alcohol-induced increase in, 626 plasma metabolites of, in schizophrenia, 510 in posttraumatic stress disorder, 1165 sensory gating deficits in relation to metabolites of, 519 twenty-four hour urinary, excretion of in posttraumatic stress disorder, 245 Caadate nucleus iron concentration in, increase of by neuroleptic drugs, 139 Cell membrane affinity for lithium ion, 795 Cellular nutrition in psychoimmunology, I-ed Central nervous system (CNS) abnormalities of, vitamin B,2 and folate deficiency-associated, 126 damage to, schizophrenia risk and, 328 lactate increase in during lactate infusion, 193 serotonergic responsivity, in normal adults, 1143 structural characteristics, in schizophrenia, 1331 Central nervous system (CNS) age-related progressive degenerative process in, in neuroleptic-delayed responsive psychotics, 205
Subject Index to Volume 27
Cerebral blood flow regional, in schizophrenia, 377 Cerebrospinai fluid (CSF) arginine vasopressin levels in, 1249 ascorbic acid concentration in, 891 dopamine levels m, 1179 galanin levels in, 923 5-HIAA levels in, 95, 311,319, 459-1e, 489, 891,926, 117P homov~iilic acid levels in, 891, 1179 MHPG levels in, 626, 1179 monoamine metabolism, in neuroleptic malignant ~yndrome, 280 norepinephrine levels in, 4, 1179 rabbit, lactate-induced electrolyte changes in, 104 uric acid concentration in, 891 c-Harvey ras-I gene linkage analysis in bipolar family and, 241 Children plasma dexamethasone levels in, 592 schizophrenic, impaired attention in, 1103 Chiordiazepoxide CRF interaction with, 953 Chloride ions plasma concentrations of, lactate-induced panic attacks and, 104 m-Chloropbenylpiperazine prolactin response to, 1143 Chlo.,promazine autoantibody presence associated with chronic administration of, 747 in beagles, 1264 iron chelated by, 138 no interference with action of anti-HLA-Al antibodies by, 642 polyclonai lgM autoantibody production associated with, 863 Cholesterol elevated serum, as risk factor for cardiovascular disease, 99 Cholinesterase inhibitors, against hypomania, 109 isozymes, quantitative analyses of' 871 Circadian rhythms of core body temperature in depression, 39 Circulatory disease family history of, as risk factor for cardiovascular disease, 99 Clinicai polysomnogram nocturnal, narcolepsy assessed via, 1057 Clomipramine
BIOLPSYCHIATRY 1990;27:1350-1365
1353
against obsessive-compulsive disorder, 95, 319, 1083 against Tourette's syndrome, 95 Clonazepam against postural myoclonus, ! 116 Clonidine against depression, 802-1e, 803-1e (response) against obsessive-compulsive disorder, 1083 against panic disorder, 802-1e, 803-1e (response) Ciozapine in beagles, 1264 CNS. See Central nervous system Cognitive impairment in ~,,.o~xia n~rvosa, 549 in bipolar disorder, midsagittal ~,'ea brain structures and, 1188 in bulimia ncrvosa, 549 in chronic schizophrenia, 150, 377 histidinemia assciated with, 69 vitamin B,2 and folate effect on, 125 Co-morbidity effect of on linkage studies of psychiatric disorders, 241 Competitive protein binding assay plasma co~isol concentrations measured via, 159 Complex partial seizure disorders kindling as model for, 249 (comntent) Computerized tomography (CT) scan basal ganglia mineralization assessed via, i 38 neuro~natomy of brain in schizophrenia assessed via, 61 progressive ventricular enlargement assessed via, 341 sulcal size in neuroleptic-~, duced akathisia assessed via, 466-1e third ventricle assessed via, 265 Continuous Performance Task impaired attention assessed via, 1133 Controlled Substances Act steroids scheduled under, 561-ed Convulsive therapies model for effects of, 76 (comment) Core body temperature in depression, circadian rhythms of, 39 Correspondence Antiseptal autoantibodies in schizophrenia, 681, 681 (response) Basal ganglia calcification in schizophrenia, 682 Clonidine, cortisol, panic disorder, and depression, 802, 803 (response) Dexamethasone suppression test in Brazil, 678 Fluoxetine in refractory depression, 461
1354
BIOLPSYCHIATRY 1990;27:1350-1365
Hirsutism in women with chronic psychiatric illness, 460 Humming, auditory hallucinations, and dystonia, 934 Lorazepam and anticholinergics in tardive akathisia, 463 Melanocyte-stimulating hormone in tardive dyskinesia, 676, 677 (response) Metoprolol versus propranolol, 673 Olfactory functioning in schizophrenia and depression, 457, 458 (response) Panic attacks end multiple sclerosis, 672 Paradoxical mood changes during pharmacotherapy of bipolar patients, 1183 Rapid cycling following antidepressant in an adolescent, 1184 Rhythmic movements of chronic akathisia, 465 Sulcal size and neuroleptic-induced akathisia, 466 L-Tryptophan in neuroleptic-induced akathisia, 671 Verapamil in stuttering, 680 Waking in a lighted room, 372 Cortical atrophy in elderly depressives, prior ECT associated with, 102 Corticosteroids ~uicidality correlated with psychosis induced by, 459-1e Corticosterone CRH-induced release of, 1094 Corticotropin-releasing factor (CRF) antidepressant and anxiolytie drug interaction with, 953 challenge, ACTH secretion in response to in depression, 938 CSF, in nervous and normal pointer dogs, 791 in depression, 938 -reduced anorexia, decrease in, 1094 limbic-hypothalamic overdrive-caused hypersecretion of, 160 Cortisol in bulimia, 1021 circadian rhythm, in eating disorders, 1007 escape, arginine vasopressin role in, 1249 after DST in Parkinson's disease, 581 clonidine effect on, 802-1e, 803-1e (response) plasma concentrations of, 159 postdexamethasone values of, 601 serum, symptom severity in depression and, 311 L-tryptophan effect on values of, 601
Subject Index to Volume 27
twenty-four hour urinary, excretion of in posttraumatic stress disorder, 245 CRF. See Corticotropin-releasing factor CSF. See Cerebrospinal fluid Cycloid illnesses psychosurgery against, 363 Cytogenetic testing for fragile X syndrome, 225 Delta wave analysis sleep-related growth hormone secretion and, 497 Delusions mineral accumulation-induced, 143 Dementia vitamin Bn and folate deficiencies associated with, 125 Depression ACTH in, 930, 938 age-adjusted threshold values for reduced REM latency in, 841 aging and, 311 alcoholism-associated, 31,478 antithyroid antibodies in, 51 arginine vasopressin secretion impaired in, 1249 bulimia nervosa as biological variant of, 454 ~:cll-mcdiatcd immune fu~.-',~ionreduced in, 22 cholinergic REM sleep induction in, 441 circadian typology of, 39 cortical atrophy in, 102 cortisol in, 159, 311,802-1e, 803-1e (response) CRF activity and, 938, 953 decision disorders in, 813 dexamethasone concentrations in, 59, 311,990, 1156, 1249 differential prediction of vegetative and cognitive symptoms in, 3! 1 DST in, 59, 311,990, 1156, 1249 ECT against, 76 (comment), 102, 289 fatigue in, 2-ed folate levels in, ! 25 geriatric onset, sleep disturbances in, 431 growth hormone secretion in, 1065, 1227 HLA antigens in, 664 HPA axis abnormalities in, 601,930, i 156 5-HIAA in, 489 5HT2 receptor changes in, 489 immune function reduced in, 22 inositol-l-phosphatase levels in, before and after lithium treatment, 552 insomnia in~ 431 learned helplessness model of, 546
Subject Index to Volume 27
LHRH in, 1065 limbic seizures and, 249 (coi~ment) multiplicity of episodes in, 115~ olfactory functioning impaired in, 457-1e, 458-1e (response) Parkinson's disease-associated, 581 psychosurgery against, 363 REM latency as diagnostic test for, 990 sensory gating deficit in, 519 TSH in, 472 vasopressin neurophysin in, 1249 ventricle/brain ratio in, 102, 342 Desipramine length of time required for elimination of from system, 657 (comment) Developmental disability fragile X syndrome role in, 223 Dexameth~.sone ACTH suppressed by, 930 free fatty acid levels increased by, 854 insulin levels increased by, 854 plasma, concentrations of, 159 resistance, hypereortisolism in psychiatric disorders and, 937 t.-tryptophan availability reduced by, 854 Dexamethasone snppression test (DST) in Brazil, 678-le in bulimia, 1021 cortisol response to, 601, 1249 depression assessed via, 59, 311,990, 1156, 1249 diagnostic efficacy of plasma and salivary, 897 in nondepressed bulimics, 454 Parkinson's disease and, 58! plasma dexamethasone concentrations and, 159, 592 reserpine-induced nonsuppression in, 546 serial, in psychiatric inpatients, 609 |.-tryptophan response to, 601 vasopressin neurophysin levels after, 1249 Diagnostic Interview Schedule lifetime history of depression determined by, 3 I Diazepam in beagles, 1264 growth hormone secretion and, 702 Diencephalon stimulation of, beneficial effects of ECT and, 1282 Diet in bulimia nervosa, nomdmnergic disturbances and, 4
eiOL PSYCHIATRY 1990;27:1350-1365
1355
Differential reinforcement of response duration in dogs, 1264 Discrimination assessment of, 813 Disso~.ation in multiple personality disorder, 1045 DNA marker studies of affective disorders, 241 Dominant accentuation theory of beneficial effects of ECT, 1282 Dopamine amphetamine effect on wave size mediated by, 184 cistemal CSF and plasma concentrations of, 1179
hypothesis, of schizophrenia, 510, 661, 1023, 103~ Dopamine-beta-hydroxylase in schizophrenia, ! 176 Dopamine D-2 receptor modulatory effect of iron on, 138 Down's syndrome brainstem auditory-evo~'ed response in, with and without sedation, 834 Dreams
involuntary nature of, I 186-ed Drug-free period length of prior to biological evaluation, 657 (comment) DSP-4 neurotoxin selective iesioning of central noradrenergic nerve terminals via, 184 DST. See Dexamethasone suppression test Dynamic single-photon emission computed tomography regional cerebral blood flow in chronic schizophrenics assessed via, 377 Dysthymia sleep patterns in, 649 Dystonia sensory ~cks for relief of, 934-1e ECG. See Electrocardiogram ECT. See Electroconvulsive therapy Edinburgh lp,ventory handedness assessed via, 62 Editorial The black hole of trauma, 469 The concept of the unconscious, i 185 Lithium research: state of the art, ! 279 A national health program for the USA, 123
1356
BIOLPSYCHIATRY
Subject Index to Volume 27
1990;27:1350-1365
Psychoimmunology and cellular nutrition: an alternative hypothesis, 1 Psychotropic drug development: challenge and promise, 1061 Redundant publication, 375 Steroids and ~thecontrolled substance act, 561 The undeveloped countries: biological psychiatry in India, 687 Voiced images, imagined voices, 811 E.~G. See E|ectro~ncephalogram Elderly anemia in, 125 cortical atrophy in depressed, 102 sleep patterns in depressed, 431 vitamin B,2 and folate status in, 125 Electricity in convulsive therapy, 76 (comment) Electrocardiogram (ECG) amytriptyline effects assessed via, 1053 Electroconvulsive therapy (ECT) brain T! levels following, ! 16 free thyroxine index decrease after, 784 -induced seizures, hyperventilation role in prolongation of, 799 mechanisms of action for, 1282 memory impairment induced by, vasopressin alleviation of, 289 mood disorders treated via', 76 (comment) structural brain changes related to, 102 Electroencephalogram (EEG) delta wave activity measured via, 497 ECT mechanisms of action assessed via, 1282 fast frequency activity, in sons of alcoholics, 631 power spectrum profile, in schizophrenia, 1331 sleep recordings, 432, 477,649 waking, quantitative indices for evaluation of in ¢lepression, 757 Electr¢[ytes changes in e;vels of, after lactate infusion, 104 Enalapril against self-induced water itRoxication, 787 {3-Endorphin after DST in Parkinson's disease, t~Sl Epilepsy limbic, kindling model and, 249 (¢'omment) Epinephrine in posttraumatic stres.~ disorder, 2~.5, 1165 Ethanol challenge: plasma GABA-like activity in :esponse to, 617
Event-related brain potential in combat veterans with postuaumatic stress disorder, 419 correlates, of impaired attention, 1103 Excessive daytime sleepiness in narcolepsy, i057 Exercise serum lactate levels during, in anxiety disorder patients, 411 Eye movements as indicator for schizophrenk~, 70, 975 Fatigue depression characterized by, 2-ed Fatty. acids free, dexamethasone effect on levels of, 854 long-chain, immune system cell utilization of, I -ed Fenfluramine prolactin response to, ! 143 Finger movement abnormal, neuroleptic-associated, 1116 Fluorescent polarization immunoassay plasma cortisol concentrations measured via, 159 Fluoxetine against obsessive-compulsive disorder, 319, 1083 against refractory depressiun, 461-1e Flupenthixoi against schizophrenia, | " "~3 Flurothyl in convulsive therapy, 76 (comm:nt) Fluvoxamine against obsessive-compulsive disorder, 319, 1083 Folate serum, in geriatric psychiatric patients, 125 Follicle stimulating hormone (FSH) in bulimia, 1021 Forskolin adenylate cyclase activity stimulated by, 735 Fragile X syndrome specific patterns of psychiatric d.lsturbance caused by, 223 Frontal lobes of psychiatric patients, brain Ti in, 116 in schizophrenia, abnormalities in, 1038 GABA. See Gamma-aminebutyric acid Galanin CSF levels of, 923
Subject Index to Volume 27
Gambling pathological, CSF galanin levels in, 923 Gamma-aminobutyric acid (GABA) benzodiazepine effect on inhibitory neuronal properties of, 702 -benzodiazepine receptor mechanism, CRF interaction with, 953 -like activity, in response to ethanol challenge, 617 uptake sites, hippocarnpal in schizophrenia, 1038 Gender anxiety ~isorders and, cardiovascular disease associated with, CNS serotonergic responsivity and, 1143 electrodermal activity in schi:opluenia and, 328 fragile X syndrome-caused psychiat,-ic disturbances specific to, 223 Gene penc'rance effect of on linkage studies of psychiatric disorders, 241 Globus pallidus iron deposition in, 143 neuronal cell loss in ..rid m~:neralization of in schizophrenia, 138 Glur.ocorticoid feedback inhibition dexamethasone resistance to, 937 Glucose immune system cell utilization of, I-ed infusion, GHRH-induc~d GH release not suppressed by in anorexia nervosa, 215 Glucose-6-phosphate dehydrogenase linkage ansiysi~ in bipolar family and, 241 Glutamine immune sy.+~m cell utiiization of, l-ed Glutaminolysis as dynamic buffer, 1-ed Growth hormone (GH) in bulimia, 1021 circadian rhythm, in eating disorders, 1007 cionidine effect on levels of, 1083 in dep,,ression, 1227, 1065 diazepam effect on levels of, 702 exaggerated response of to GHRH ~n anore×ia nervosa, 215 respox~se to TRh in panic disorder, 1227 secretion, at sh:ep onset, 497 Growti3 hormone-releasing hormone (GHRH) exaggerated GH response to in anorexia nervosa,
Hallucination
BIOLPSYCHIATRY 1990;27:1350-1365
1357
mine~'al accumui,qtion-induced, 143 Halope~,~ol amphetamine inhibitiott of sensory gating reversed by, 183 in beagles, 1264 blink rate response to, 113 plasma c~iolinestemse isozyme levels affected by, 871 against schizophrenia, 510 -stimulate~ pt~!actin in schizophrenia, 1203 t~dlve dyskinesia caused by, 139 in third cerebral ventricle assessment, 205 against Tourette's syndrome, 95 Hamilton Depression Scale serum folate levels in major ~lepression correlated with scores on, 126 Heart rate in anxiety disorders, TRH effect on, 781 clonidine effect on levels of, 1083 in posttraumatic stress d~sorder, 1165 Hemispheric dysfunctions resolution of, beneficial effects of ECT and, 1282 Herpes simplex virus latent, lithium-induced inhibition of reactivation of, 447 Hexafluorodiethylether in convulsive therapy, 76 (comment) 5-1-11AA. See 5-Hydroxyindole acetic acid Hibernation changes in energy balance in, behavioral abnormalities in depression compared to, +~ Hippocampus auditory sensory gating model involving neurons in, 183 GABA uptake sites in, in schizoph'enia, 1038 lithium effect on synapfic transmissions in CAI aeurones in, 174 Hirsutism female, in chronic psychiatric illness, 4fi0-1e Histidinemia heterozygosity for, in schizophrenia, 69 HLA aatigens in depression and hypersomnia, 664 HLA-AI alloantibodies directed against, no evidence of chlorpromazine interference with action of, 642 Holter monitoring ECG effects of amitriptyline assessed via, i053 Homovanillic acid
1358
Subject Index to Volume 27
BIOL PSYCHIATRY 1q90:27:!350--1365
CSF levels of, 280, g91, 1179 plasma concentrations of, ! 179 in schizophrenics, after haloperidol treatment, 510 HPA axis activity, in nervous and normal pointer dogs, 79! in bulimia, 1021 in depression, 601,930, 1156 disirdaibited corfisol secretion due t-~ abnormalities in, 159 Humming auditory hallucinations reduced via, 934-1e 5-Hydroxyindole acetic acid (5-HIAA) CSF concentrations of, 891,926, 1179 in depression, 31 !, 489 in neuroleptic malignant syndrome, 280 in obsessive-compulsive disorder, 95, 319 plasma concentrations of, 891,926, ! 179 among suicidally depressed patients, 459-1e in Tourette's syndrome, 95 5-Hydro.~ytryptamine receptor changes, in major depression, 489 Hyperactivity fragile X syndrome role in, 223 Hypercertise!!sm neural bases of, 937 Hyperglycemia in acute phase anorexia ncrvosa, inhibitory action of on GHRH-induced GH release lost in, 215 concmrent with hyperventilation, serum lactate rise induced by, 411 Hypersomnia in affective disorders, 372-1e HLA antigens in, 664 Hypertension as risk f ~ o r for e.~rdio,~asculardisease, 99 Hyperthyroidism thyroid autoimmuni~y as c~,~se of, 51 Hyperventilatio, during ECT. seizure., length and. 790 voluntary, during tatw ,,enic hyperglycemia to induce panic attacks, 41 | Hypoadrenocortism neural bases of, 937 Hypocapnia seizures and, 799 Hypo"ronta!ity .~ in thronic schizophrenia, 377 Hypothalamus
decreased noradrenergic turnover in, food reduction and, 5 paravemricular nuclei of, galanin-like immunoreactivity in, 923 Hypothyroidism subclinical, as risk factor for affective disorder, 52 thyroid autoimmunity as cause of, 51 Ideas of influence mineral accumuiation-iaduced, i43 Ideas of reference mineral accumulation-induced, 143 antibodies, in mental disorders, 747, 863 IgM antibodies, in mental disorders, 747 neuroleptic-associated, prevalence of, 863 Imipramine against atypicel depression, 442 CRF interaction with, 953 paradoxical mood changes upon withdrawal of, I 183-1e
tritiated, binding of to piare|ets L-,.obsessivecompulsive disorder, 319 ~mmune function ~,mpaired, psychological stress and, l-ed reduced cell-mediated, in depression and stress, 22 India biological psychiatry in, 687-ed Indoklon in convulsive therapy, 76 (comment) Inositol- l-phosphatase red blood cell, lithium inhibition of, 532 Insomnia depression-associated, 431 Insulin dexamethasone effect on levels of, 854 • ,.vv,u,,t~,~
/i~O'¢¢,ili~iitS
abnormal, in chronic schizoph~.ia, 150 Iron
role of in schizophrenia, 1~8, 143 Kindling phenomenon beneficial efft~ts of ECT and, 1282 limbic epilepsy and, 249 (comment)
-induced panic attacks, hyperventi~atic,n role in, 411
Subject Index to Volume 27
infusion, CNS effects of, 193 panic attacks induced by, 104 Language disorder fragile X syndrome role in, 224 Latency reduction visual evoked potential, in schizophrenia, 400 Lateral ventricular enlargement in schizophrenia, 61, 102, 1331 Learned helplessness model of depression, DST nonsuppression in, 546 Leprosy lepromatous, antibodies in, 863 l_euco~omy .,~,. against psychiatric illness, 363 Leukoaraiosis in asy~aptomatic adult offspring of Alzheimer's disease patients, 1244 LH. See Luteiuizing hormone LHRH. See Luteinizing hormone-releasing hormone Light treatment with bright, effect of on core body temperature in seasonal affective disorder, 39 Limbic encephalitis paraneoplastic, 529 Limbic system schizophrenia and, 329 Linkage studies of psychiatric disorders, effects of co-morbidity and gene penetrance on, 241 Lithium auditory-evoked potentials affected by, 555 brain TI levels after treatment with, 116 effect of on synaptic transmissions, in rat hippocampus CAI neuron,s, 174 exposure to, antithyroid antibody presence unrelated to, 51 in healthy volunteers, 711 HLA-A3 ~sociated wi!b negative ~_~-se_*_~. inhibiti~m, of myo-inositol-l-phosphatase, 552 ion, re0uced cell membrane affinity for, 795 ~ against latent herpes simplex virus, 447 manic state induced by, 1184-Ie paradoxical mood changes upoa withdrawal of, 1183-Ie prophylaxis, folate supplementation of, 126 r~seareh, 1279-ed I..OATS computer analysis system CT s¢~l films analyzed via, 138. 143
BIOLPSYCHIATRY 1990;27:1350-1365
1359
Locus coeruleus firing of, sweet water consumption role in ~duced, 5 galanin-like immunoreactivily in, 923 Lorazepam against tardive akathisia, 463-1e Lo~.ver-bandpass filter frequency P3 latency and, 667 Lupus anticoagulant antibodies neuroleptic-associated, 863 Luria*Nebraska Batter3, neurological impairment in chronic schizop~enia assessed via, 377 Luteinizing hormone (LH) in bulimia, 1021 Luteinizing hormone releasing hormone (LHRH) growth hormone response m in endogenous depression, 1065 Lymphocytes nutrition of, psycheimmunology and, l-ed responses of to mitogenic stimulation, reduction of due to depression and stress, 22 Macrophages nutrition of, psychoimmunology and, l-ed Magnetic resonance imaging (MRI) Alzheimer's disease-~elated whtte matter changeb assessed via, 1244 brain TI measured via, 116 of cerebral structares, in bipolar disorder, 1188 controlled multiplanar, schizophrenia assessed via, 61 midbrain ventral tegmentum assessed via, 661 serial, ECT-t~eated depressives assessed via, 102 ~emperal lobe abnormalities in panic disorder assesse~ v~a, 3 ~ Malnutrition schizophrenia risk and, 328 Mania ar~in~e vasop~ssin function in, !249 decision disorders in, 813 lithium-induced, 1184-~e physostigmi~ ~g~nst, 109 psychosurgery against, 363 R$ 86 against, 109 sensory gating deficit in, 519 Manic depressive disorder circadian temperature rhythms ie, 40 inositol-l-pbosphatase leveis in, bef¢,re and after lithium treatment, 552 psychosurgery against, 363
1360
BIOLPSYCHIATRY
Subject Index to Volume 27
1990;27:1350- ! 365
MAO. See Monoancline oxidase Mean eye scanning length in schizophreuia, 975 Meige's syndrome sensory tricks for relief of, 934-1e Melanocyte-stimulating hormone (MSH) plasma, in tardive dyskinesia, 676-1e, 677-1e (response) Melatonin circadian rhythm, in eating disorders, 1007 Memory characterization of, 1186-ed vasopressin role in, 289 Menses in bulimia nervosa, noradrenergic disturbances and, 4 Mental impairment histidiaemia associated with, 69 mineral accumulation-induced, 143 Me.~tal retardatic,u fr~,gile X syndrome role i~, 223 self-injurious behavior hi, haltrexone against, 741 Methylphenidate blink rate response to, I 1~ Metoprolol against neuroleptic-induced ~athisia, 673-1e Metrazol in convulsive therapy, 76 (comm:nt) MHPG age-related increase of, in detoxifieo alcoholics, 626 cisternal CSF and plasma concentrations of, ! 179 clonidine effect ~n, 1083 CSF levels of, in neuroleptie malignant syndrome, 280 plasma levels of in schizophrenics, after haloperidol treatment, 510 sensory gating deficit associ..~.te4w;.th ptasma-free levels of, 519 Midbrain tegmentum schizophrenic syndrome associated with lesion in, 661 Mini-Mental State scores in vitamin-deficient geriatric psychiatric pat~euts, 125 Mouoamine oxidase (MAO) inhibito~s, p~adoxical mood changes upon with,Irawe! of, 1133..le platelet, in alcoholism subtL~es, 91 I Monoamit~es
CSF, metabolism of in neuroleptic malignant syndrome, 280 Mononucleosis antibodies in, 863 Motor behavior stereotypic, fragile X syndrome role in, 223 Motor dis~rbances mineral accumulation-induced, 143 MSH. See Melanocyte-sfimulating hormone Multidimensional Personality Questionnaire personality resemblance in familial alcoholism assessed via, 1305 Multiple persoaality disorder treatment of, 1045 Multiple sclerosis panic attacks in, 672-1e Multiple Sleep Latency Test narcolepsy assessed via, 1057 Myoclonus postural, neuroleptic-associated, 1116 Myositis antibodies in, 863 N40 wave auditory sensory gating and, 183 N I 0 0 latencies visual evoked potential, in schizophrenia, 401 Naloxone against self-injurious behavior, 741 Naltrexone aversiv¢ response ill drug-naive rats induced by, 543 against self-injurious beltavior, 741 Narcolepsy assessment of, 1057 National health program for the United States. 123-ed Natural killer cells cytotoxicity of, reduction of due to depression Neoplastic cells nutrition of, psychoimmunology and, l-ed Neuroleptic malignant syndrome CSF monoamine metabolism in, 280 Ne,urological i,,lpairment in chronic schizophrenia, !150, 377 Neurotransmitters synthesis of, vitamin ~absorption-associated inhibition of, 126 Neutron activation analysis aluminum tissue concentrations assessed via, 884 New Haven SchizopLrenic Scale
Subject Index to Volume 27
scores on in study of third ventricle enlargement in psychotics, 205 Nimodipine against Alzheimer's a:'~ease, 1133 Nipecotic acid radiolabeled, as marke~"of GABAergic neurons, 1038 Non-rapid eye movement (NREM) sleep patterns, during alcohe~ withdrawal, 477 Norepinephrine amphetamine blockade of paired stimulus suppression mediated by, 184 cisternal CSF and plasma concentrations of, 1179
in neuroleptic malignant syndrome, 280 neurons, galanin as cotransmitter with, 923 plasma, during bingeing and vomiting, 4 in posttraumatit; sh~ess dise,rder, 1 ! 66 system, in schizophrenic F,iychopatho!ogy, 510 twenty-four hour urinary, excretion of in posttraumatic stress disorder, 245 NREM. See Non-rapid eye movement Obesity hormonal circadian rhythms in. 1007 Obsessive-compulsive disorder a2-adrenoreceptor status in, 1083 clomipramine against, 95 tritiated imipramine binding in, 319 Obstetrical complications schizophrenia ~isk and, 328 Olfactory functioning impaired, in schizoi~ertia and depression, 457-1e, 458-1e (rcspons::) Opioid antagonists receptor-mediated aversive effects of, 543 Overuse syndrome immunopsychological role in-ed, 2 P3 latency i~? schi:zophrenia, 667 P50 auditory-evoked potential sensory gating and, i84, 519 suppression, in schizop~'m~nia, !2i6 P200 latency visual evoked potential, in schizophrenia-. 400 Palladum internum iron content of in schizophrenia, 144 Panic attacks 13¢~ lactate-induced, 104, ,n., in multiple sclerosis, 672-1e Panic disorder
r :OLPSYCHIATRY 1990 27: i 350-1365
1361
five percent carbon dioxide ~hallenge-induced response similar to, 689 growth hormone response to TRH in, 1227 hyperventilation-induced inct.~ase in serum lactate during, 41 ! serum cholesterol levels in, 9~ skin conductance habituation i:t, 1231 tempor~! lobe abnormalities in, 304 TRH effect on blood pressure and heart rate Lq, 7gl Paranoia frontal cerebral flow deficits in, 377 Parkinsonism neuroleptic~a~sociated, 1 ! 16 Parkinson's disease ~CTH in after DST, 5~1 cortisol in after DST, 581 I~-endorphin in after DST, 581 PEG. See Pneumoencephalography Penlobarbital CRF interaction with, 953 Pentylenetetrazoi in convulsive therapy, 76 (comment) Perseveration fragile X syndrome role in, 223 Personality resemblance in relatives of male alc~.holics, i305 Phenelzine against atypical depression, 442 paradox;eal mood changes upon withdrawal of, ! 183-1e
Pi~enothiazines polyclonal IgM elevation associated with, 863 l~.~enytoin hair growt~h ~ndueed by, 460-1e Phobia TRH effect on blood pressure and heart rate in, 781 Phosphate plasma concentrations of, la4"~ate-induced punic mtacks and, 104 Phosphatidylino~sitol reduced syn~,esis of after lithk'm ra~atmet t, 552 Ph~spholipa~e C in posttranmatic stress disorder, 735 Physical acfiviq¢ noradrenergi¢ dist~rhances and, 4 Physostigmine ~ainst hypo~rmnia, 109 Filo~~vine h'Lh_b~,m~coadministration, limbic seizures i~duced by, 552
1362
tool PSYCHIATRY
Subject Index to Volume 27
199~%27:1350-1365
Pimozide against Tourette's syndrome, 95 Pneumoencephalography (PEG) progressive ventricular enlargement in chronic schizophrenia assessed via, 341 Postmortem studies iron deposition assesses via. 138. i43 Posttraumatic stress disorder autonomic responses to stress in. 1165 cortisol and catecholamine excretion in. 245 domination of though*~sby traumatic events in. 469-ed event-related brain potentials in. 419 I>2 reduction in. 419 phospholipase C activity in. 735 platelet adenylate cyclase activity in. 735 Prenatal complications schizophrenia risk and. 328 Procyclidine against tardive akathisia. 463-1e Prolactin basal and haioperidol-stimulaicd, in schizophrenL~. 1203 in bulimia. 1021 eireadi~.n rhythm, in e.ating d~st.rders. 1007 fenfluraznine-induced. ! 143 response of to TRH in a~eoholics. 31 Pra0ranolol bias deficit of expressior~ modeled by. 813 against neuroleptic-indu:ed akathisia. 673-1e Prostat..alndin E~ adenylate cyclase activity stimulated by. 735 Proton longit,dl ,al relaxation time (1"1) brain. MRI u:easurement of. ! 16 Pseudocholineslerase levels, quantitative analysis of. 871 Psychoimmunology brain involvement in immune system and. l-ed Psycho-G:ganie syndrome as accompanimem of open leucotomy. 363 Psychopathology in chronic schizophrenia. 150 esychosi~ captopdl-induccd, 968 cerebral third ventricle enlargement in, 2(~5 circular, psychosurgery against, 363 corticosteroid-indu¢,~d, suicidality in, 459-Ie epileptic, 7:49 (comment) methamph~;tamine, eye movements in, 975 mineral aeculnulation-induced, 143 organic, low vitamin B j2 levels associs~=d with, i25
visu~d evoked potential correlates of clinical symptomatology in, 400 Psychosurgery indications for, 363 Purine nucleotide synthesis pathway for, precise regulation of, I-ed Pyriraidine nucleotide synthesis pathway for, precise regulation of, l-ed Quantitative slab gel electrophoresis plasma ~.holinesterase isozyme ievels assessed via, 871 RA24 ambulatory rest-activity monitor circadian rest-activity rhythm alte.r~tions assessed via, 563 Radioimmunoassay plasma dexamethasone concentrations measured via, 159 Rapid eye movement (REM) latency, 649, 841,990 in narcolepsy, 1057 patterns, in geriatric depressed p~fients, 431 sleep patterns, during alcohol withdrawal, 477 Receiving operator characteristic analysis REM latency and, 841,990 Red blt~l cells inositol-l-phosphatase in, lithium inhibitio~ of, 552 Reserpine DST nonsuppression induced by, 546 Response bias assessment of, 813 Response Search Score eye movements scored via, 975 Rest-activity rhythm circadian, alterations in, 563 Restraint stress -induced ~,orexia, decrease in, 1094 Rheu~natoid arthritis antibodies in, 863 Rheumatoid factor antibodies, in chronic mental disorders, 747 neuroleptic-associated, pr~v-al~,lccof, 863 Rituals compulsive, clomipramine against, 95 RS 86 against Alzheimer's disease, 109 as specific muscarinic agonist, i~ manic disorde[, 109 Saline
Subject Index to Volume 27
infusion, GHRH-induced GH release stimulated b.'., in anorexia nervosa, 2!5 Saliva DST, 897 ~chizoaffective disorder ar,~:.thyroid antibodies in, 51 ECT mechanisms of action in, 12~2 Schizophrenia abnormal voluntary movements in, 150 anti-HLA-Al antisera in, 642 antinuclear antibodies in, 747 antiseptal autoantibodies in, 681-1e, 681-1e (response) ~ttention deficits in, 1103 auditory-evnked response in, 1216 basal ganglia mineralization in, 138, 143, 682-1e blink rate in, 113, 1197 cerebral third ventricle assessment in, 205 chronic, abnormal involu~.tary movements in, 150 CNS lactate levels in, 194 CNS structural characteristics in, 1331 cognitive impairment in, 150, 377 convulsive therapy against, 76 (comment) diminished evoked response to repeated auditory stimuli absent in, 183 dopamine-beta-hydroxylase in, ! 176 dopan:ine hypothesis of, 510, 661, 1023, 1038 ECT mechanisms of action in, 1282 LEG power spectrum pronle in, 1331 ele~trodermal activity correlated to season of ~.~th in, 328 event-related potential correlates of impaired attentio~ in, 1103 eye movements in, 70, 975 haloperidol agai~t, 113 hippocampal GABA uptake sites in, 1038 histidinemia associated with, 69 hypofrontality and cognitive i.,np;ah~nent in, 377 involuntary ~.,~vements in, 150 lateral ventricular enlargement in, 61,102, 1331 left hemisphere overactivation in, 378 limbic system and, 329 neurological impairment in, 150, 377 neuropathology of, 353 olfactory functio_,,.in~impaired in, 457-~,~, 458-1e (response) P3 latencies in, 667 PSO potential in, 1216 p!asma catecholamine metabolites in, 510 polydypsia in, 787 positive/negative symptom dichotomy in, 1323
BIOL PSYCHIATRY ! 990;27:1350- ! 365
1363
postural myoclonus in, neuroleptic-assoeiated, 1116 progressive ventricuiar enlargement in, 341 prolactin levels in, 1203 psychopathology of, 150 sensory gating deficit in, 519 sensory trick phenomena in, 934-1e in siblings, 61 [3H]-spiperone binding to intact lymphocytes as biological marker for, 1327 suicidality in, CSF 5-HIAA levels correlated with, 926 temporal lobe abnormalities in, 61, 1038 two-subtype concept of, 510 urinary chromatographic analysis in, 1127 ventricle/brain rat~o in, 61 visual evoked potential and, 490 Scleroderma antibodies in, 863 Season of birth, electrode~mal unresponsiveness in schizophrenia correlated too 328 Seasonal affective disorder core body temperature in, light treatment effec~ on, 39 Sed2tio~ effect of on brainstem auditory-evoked response, 834 Seizures during EL'T, prolongation of by hyperventilation, 799 Self-injurious behavior fragile X syndrome role and, 223 in mental retardation, naltrexone against, 741 Sensitization theory of beneficial effects of ECT, 1282 Sensory gating auditory, rat hippocampal neuron model of, 183 deficits, 519, 1216 Sensory trick phenomena dystonia relieved via, 934-1e Serotonin hypothesis, of obsessive-compulsive disorder, 319, 1083 synthesis of, vitamin malab~tion-assecia~ed inhibition of, 126 Siblings schizophrenic, bilateral reduction in temporal lobe area in, 61 Signal detectio~ theory. response bias assessed via, 813 Skeletal muscle
1364
BIOLPSYCHIATRY
Subject Index to Volume 27
1990~27:1350-I365
role of in psychological stress, brain and immune system interaction and, l-ed Skin conductance habituation, in panic disorder, 1231 Sleep excessive daytime, HLA :ntigens in, 664 in dysthymic patients, 649 in geriatric depressed population, 431 narcoleptic, 1057 in nondepressed bulirmcs, 454 onset, growth hormone secretion during, 497 during withdrawal from pure primary alcoholism, 477 Smell identification test olfactory functioning in schizophrenia and depression assessed via, 457-1e Smoking reduction in natural killer cell cytotoxicity not associated with, 22 as risk factor for cardiovascular disease, 99 Smooth pursuit eye movement evaluation in schizophrenia, 70 Sobriety dun~tion of correlated with sleep patterns. 477 Sodium b~.'lance, noradrenergic function 8nd, 5 Sodium la .*~te infusion, pamc attacks precipitated by, 104 Speech impairments histidinemia associated with, 69 ['~H]-Spipemne binding, to intact peripheral blood lymphocytes, 1327 Starvation intermittent, impaired cognitive f~nction a,~d, 549 Steroids under Controlled Substances Act, 561-~J against ECT-iuduced memory impairment, 289 Stress autenomic responses to, in posttraumatic stress disorder, 1165 chronic, physiological responses in, 22 hirsuti~m tnduced by emotional, 460-1e -induced ~norexia, I094 life, reduced celt-mediated immune function in, 22 psychological impaired immune function and. l-ed
S~ttering verapar~il in, 6~0-1e Subaffecti,~edysthymic disorder sleep patterns in, 649
Substance abuse in monozygotic twins, heritability of, 1293 Substantia nigra iron pigment deposition in, 139, 143 Suicidality anxiety disorders and, 99 CRF activity and, 95¢ CSF 5-HIAA levels and, 926 serotonergic function and, 926 Suprachiasmatic nucleus morphological changes in, aging and, 563 Sympathetic nervous system activation of by bingeing and vomiting, 4 Systemic lupus erythematosus antibodies in, 863 TI. See Proton longitudinal relaxation time T3. See Triiodothymnine T4. See Thyroxine Tardive dyskinesia haloperidol overdose-indu,.ed, iron pigment deposition in, !39 neuroleptic-asscciated, I 116 plasma MSH in, 676-1e, 677-1e (response) Temperature ambient, schizophrenia risk and, 328 Temporal lobes in epilepsy, 10~5 in panic disorder, 304 of psychiatric patients, brain TI in, 116 in schizophrenia, 61, 1038 Tension predisposing to alcoholism, plasma GABA-like activity as biological marker for, 617 Thioridazine in beagles, 1264 birsutism induced by, 460-Ie Third ventricle cerebral, enlargement of in psychotics, 205 Thyroiditis autoimmune, psychiatric effcct~ of, 51 Thyrotropin (TSH) response to TRH, 31,472, 905, 1021 serum levels, in endogenous depression, 472 Thyrotropin-releasing bormone (TRH) blood pressure and, 781 growth hormone r~ ponse to, 1065, 1227 heart rate and, 781 prolactin response to, 3 ! TSH response to, 31,472, 905~ I ~ 1 Ti~yruxine (T4) free, POst-ECT fall in, 784 serum levels, in endogenous depression, 472
Subject Index to Volume 27
Tics multiple, clomipramine agaimL 95 Tourette's syndrome elomipramiiie against, 95 Trauma memow-evoking cues of, in posttraumade stress ~sorder, 1165 TRH. See Thyrotropin-releasing honr.one Tricvclic antidepressants ca'.~liotoxicity of, 1(~53 against obses~ive-compulsive disorder, 95 paradoxical mood changes upon withdrawal of, 1183-1e
rapid cyclh~g induce~ by. 1184-1e against Tourette's syndrome. 95 Triiodothyronine (T3) levels, in endogenous depression. 472 Trimipramine rapid cycling induced by. 1184-1c Tritium film autoradiography 5HT, recept¢, studied via~ 489 L-Tryptophan availability of. in depressed females. 601 dexamethasone effect on availability of, 854 membrane transport, in erythrocytes. 723 in neuroleptic-induced akathisia. 67 l-le prolactin response to. 1143 TSH, See Thyrotropin Tumor~ solid, antibodies in, 863 Twins monozygotic, heritability of substance abuse and antisocial behavior in, 1293 Two-subtype concept of schizophrenia, 510 Type A behavior as risk factor for cardiovascular disease, 99 L-Tyro,sine membrane transport, in erythrocytes, 723 Unconscious concept of 1185-ed Uric acid CSF concentr,,~ion gradients of, 891 Urine chromatographic an.:lysis, in schizophrenia, !12'/ ~'~sopressin ECT*induced memory impairment relieved by, 289 neurophysin, in depression, 1249
BIOL PSYCHIATRY 1990;27: ! 350-1365
1365
Venlricle/brain ratio in depression, 102, 342 in schizophrenia, 61 Ventricles progressive enlargement of in schizophrenia, 341 size of, blink rate and, 113 Verapamil against stuttering, 680-1e Vigilance performance rolatkJ~,ship of to biological adaptation to starvation, 549 Violence episodic, in multiple personality disorder, 1045 Viral infections schizophrenia risk and, 328 Visual evoked lx,tentials flash, as correlates of clinical symptomatology in schizophrenia, 400 Vitamin BI2 serum, in geriatric psychiatric patients, 125 Vitamin deficiencies schizop~reni~ risk and, 328 Voluntary movements abnormal, in chronic schizophrenia, 150 Vomiting norepinephrine levels and, 4 WAIS IQ test in schizophret~i~ 70 Water intoxication self-induced, management of, 787 Wechsler Memory Test serum folate levels in major depression correlated with scores on, 126 Weight noradrenergic disturbances and, 4 White matter changes, in Alzheimer's disease, 1244 Wisconsin Card Sorting Test neurological impairment in chronic schizop~hrenia assessed via, 377 X chromosome human, MAO stmctual ~enes assigned to, 911 -linked mental retardation syndrome, fragile X syndrome originally ~escribed as, 223 Yohimbine against obsess~ve-compulsive disorder, i084 Zimelidine anti-obsessional properties of, 319
BIOLPSYCHIATRY 1990;27:1350-1365
Subject Index to Volume 27 Abnormal Involuntary Movement Scale scores on in chronic schizophrenia, 150 Acetylcholine in Alzheimer's disease, 1133 Acetylcholinesterase in Alzheimer's disease, depletion of, 373 levels, quantitative analysis of, 87 l ACTH. See Adrenocorticotropic hormone Adenylate cyclase in posttraumatic stress disorder, 735 Adolescents rapid cycling in, after antidepressant therapy, 1184-1e
ct2-Adrenergic receptors in bulimia nervosa, 5 in obsessive-compulsive disorder, 1083 {3-Adrenergic receptors in bulimia nervosa, 5 disorders of decision modulated by, 813 Adrenocorticotropic hormone (ACTH) adrenal response to, in depression, 930 circadian rhythm, in eating disorders, 1007 CRH-induced release of, 1094 CSF, in nervous and normal pointer dogs, 791 hy~rsecretion, limbic-hypothalamic overdrive~ induced, 160 in Parkinson's disease, after DST, 581 Affective disorders abnorma!~ties in daily rhythm of body temperature in, 39 antithyroid antibodies in, 51 DNA marker studies of, 241 familial, high prevalence of among nondepressed bulimics, 454 fragile X syndrome role in, 223 hypercortisolism in, 937 hypersomnia in, 372de noradrenergic/cholinergic imbalance theory of, 109 vitamin B~2 and folate effect on, 125 Aging circadian rest-activity rhythm alterations in, 563
Abbreviation ed: .F.ditonai le: Letter to the Edi:or © 1990 3ocieiy of Biological Psychiatry
CNS serotonergic responsivity and, 1143 increasing, as risk factor for cardiovascular disease, 99 reduction in natural killer cell cytotoxicity not associated with, 22 symptom severity in depression and, 311 AIDS. See Autoimmunodeficiency syndrome Akathisia chronic, rhythmic movements of, 465-1e beta-blockers against, 673-1e lorazepam and anticholinergics in, 463-1e sulcal size and, 466-1e ~-tryptophan in, 671-1e Alcohol consumption of, reduction in natural killer cell cytotoxicity not associated with, 22 Alcoholism CSF galanin levels in, 923 in depression, 231,478 family history of, 631,905, 1305 in monozygotic twins, heritability of, 1293 platelet MAd activity in, 91 ! pure primary, sleep patterns during withdrawal from, 477 reduced plasma GABA-like activity as biological marker for vulnerability to, 617 TSH and prolactin response to TRH in, 31 withdrawal from, age-related increase in plasma MHPG levels after, 626 Aluminum fluoride, plus sodium chloride, adenylate cyclase activity stimulated by, 735 tissue concentrations of, 884 AIzheimer's disease acetylcholinesterase in, 573 aluminum tissue concentrations in, 884 calcium channel blockers against, 1133 circadian rest-activity rhythm alterations in, 563 hypereortisolism in, 937 red cell folate and, 126 RS 86 against, 109 Amenorrhea in bulimia nervosa, noradrenergic disturbances associated with, 4 Amino acids precursors to, noradrenergic disturbances and, 4 Aminoacidopathies 0006-3223/90/$03.50
Subject Index to Volume 27
heterozygosity for more than on,~ of the loci for, 69 Amnesia vasopressin against, 289 Amphetamine sensory gating diminished by, 183 Amygdala dopamine concentration in, 1038 Anemia in geriatric psychiatric p~tic~t$, 125 Anerg~a antithyroid antibodies associated with, 52 physostigmine-induced, 109 Angiostensin-converting enzyme inhibitors antidepressant properties of, 968 Anorexia nervosa acute phase, GHRH-induced GH release lost in, 215 bulimia nervosa r~ore prevalent than, 4 cognitive performance in, 549 CRH-induced, 1094 growth hormone response to TRH in, 1227 hormonal circadian rhythms in, 1007 hypercortisolism in, 937 restraint stressDinduced, 1094 Anticardiolipin antibodies in chronic mental disorders, 747 neuroleptic-associated, 863 Anticholinergics against tardive ak2~hisia, 463-1e Anticonvulsant effec',s of ECT, 1282 Antidepressants against bufimia nervosa, 5 CRF interaction with, 953 rapid cycling upon withdrawal of, 1184-1e Antinuclear antibodies in chronic mental disorders, 747 neuroleptic-associated, prevalence of, 863 Antiphospholipid antibodies neuroleptic-associated, prevalence of, 863 Anti-Ro(SSA) antibodies in chronic mental disorders, 747 Anti-Ro(SSA)/anti-La(SSB) antibodies in chronic mental disorders, 747 Antiseptal autoantibodies in schizophrenia, 68 l-le, 68 I-le (response) Antisocial behavior in monozygotic twins, heritability of, 1293 Antithyroglobulin, frequency of in psychiatric patients, 5 ! Antithyroid antibodies frequency of in psychiatric disorders, 51
BIOLPSYCHIATRY 1990;27:1350-1365
1351
Antiviral activity of psychotropic medications, 447 Anxiety disorders cardiovascular disease risk and, 99 limbic seizures and, 249 (comment) TRH effect on blood pressure and heart rate in, 781 Anxiolytic drugs CRF interaction with, 953 Appetite in bulimia nervosa, disturbance of modulation of, 5 Arecoline REM induction test, in atypical depression, 441 Arginine vasopressin in psychiatric disorders, 1249 Arteritis antibodies in, 863 Ascorbic acid CSF concentration gradients of, 89 I Attention deficits in schizophrenic childre,, event-related potential correlates of, 1103 Auditory-evoked r~sponse brainstem, with and without sedation, 834 impaired, catecholamine metabolite levels and, 519 lithium effect on in healthy subjects, 555 in schizophrenia, 1216 Auditory hallucinations generation of, 81 i-ed humming-induced reduction of, 934-1e Autism brainstem auditory-evoked response in, with and without sedation, 834 fragile X syndrome role in, 223 Autoantibodies in chronic mental disorders, 747 Autoimmunity thyroid, as cause of hypothyroidism and hyperthyroidism, 51 Autoimmunodeficiency syndrome (AIDS) antibodies in, 863 Autosomal dominant gene single inherited, in obsessive-compulsive disorder and Tourette's syndrome, 95 Autosomal recessive disorders enzymatic activities in heterozygotes for, 69 Barbiturates in dogs, 1264 Basal ganglia calcification, in schizophrenia, 682-1e
1352
BIOLPSYCHIATRY
Subject Index to Volume 27
1990;27:1350- i 365
mineralization of, 138, 143 Bay-e-9736 calcium channel blocker against Alzheimer's disease, 1133 Benzodiazepine/GABA/chloride ionophore chloride ion involved in modulation of inhibitory neurotransmission through, 105 Benzodiazepines in dogs, 1264 against tardive akathisia, 463-Ie Beta-hydroxybutyric acid (BHBA) in bulimia, 1021 BHBA. See Beta-hydroxybutydc acid Bingeing plasma norepinephrine levels and, 4 Bipolar affective disorder antithyroid antibodies in, 51 brain TI levels in, 116 cell membrane affinity for lithium ion during, 795 circadian temperature rhythms in, 40 familial, linkage analysis of, 241 iron pigment deposition in, 139 MRI of cerebral structures in, ! 188 psychosurgery against, 363 treatment of, 1045 ventricular enlargement and, 341 Birth season of, electrodermai unresponsiveness in schizophrenia correlated to, 328 Blinking in schizophrenia, ! 13, ! 197 Blood pressure in anxiety disorders, TRH effect on, 781 clonidine effect on, 1083 in posttraumatic stress disorder, ! 165 Blood-brain barrier RS 86 passage through, 109 Body image in bulimia nervosa, disturbance of, 5 Brain interaction between immune system and, during psychological stress, l-ed Brainstem auditory-evoked response, with and without sedfition, 834 Bulimia nervosa brain T! levels in, 116 cognitive performance in, 549 growth hormone response to TRH in, 1227 normal weight, noradrenergic disturbaces in, 4 sleep patterns and dexamethasone suppression in, 454
Buspirone CRF interaction with, 953 CA1 neurones rat hippocampus, lithium effect on synaptic transmissions in, 174 Calcium chan~el blockers, against Alzheimer's disease, 1133
plasma concentrations of, lactate-induced panic attacks and, 104 Camphor in convulsive therapy, 76 (comment) Cap:opril amidepressant properties of, 968 against self-induced water intoxication, 787 Carbamazepine against multiple personality disorder, 1045 Carbon dioxide five percent challenge, in panic disorder, 689 Cardiovascular disease risk factors for in psychiatric patients, 99 Cata#exy in narcolepsy, 1057 Catatonia presence of minerals correlated with, 138 Catecholamines alcohol-induced increase in, 626 plasma metabolites of, in schizophrenia, 510 in posttraumatic stress disorder, 1165 sensory gating deficits in relation to metabolites of, 519 twenty-four hour urinary, excretion of in posttraumatic stress disorder, 245 Caadate nucleus iron concentration in, increase of by neuroleptic drugs, 139 Cell membrane affinity for lithium ion, 795 Cellular nutrition in psychoimmunology, I-ed Central nervous system (CNS) abnormalities of, vitamin B,2 and folate deficiency-associated, 126 damage to, schizophrenia risk and, 328 lactate increase in during lactate infusion, 193 serotonergic responsivity, in normal adults, 1143 structural characteristics, in schizophrenia, 1331 Central nervous system (CNS) age-related progressive degenerative process in, in neuroleptic-delayed responsive psychotics, 205
Subject Index to Volume 27
Cerebral blood flow regional, in schizophrenia, 377 Cerebrospinai fluid (CSF) arginine vasopressin levels in, 1249 ascorbic acid concentration in, 891 dopamine levels m, 1179 galanin levels in, 923 5-HIAA levels in, 95, 311,319, 459-1e, 489, 891,926, 117P homov~iilic acid levels in, 891, 1179 MHPG levels in, 626, 1179 monoamine metabolism, in neuroleptic malignant ~yndrome, 280 norepinephrine levels in, 4, 1179 rabbit, lactate-induced electrolyte changes in, 104 uric acid concentration in, 891 c-Harvey ras-I gene linkage analysis in bipolar family and, 241 Children plasma dexamethasone levels in, 592 schizophrenic, impaired attention in, 1103 Chiordiazepoxide CRF interaction with, 953 Chloride ions plasma concentrations of, lactate-induced panic attacks and, 104 m-Chloropbenylpiperazine prolactin response to, 1143 Chlo.,promazine autoantibody presence associated with chronic administration of, 747 in beagles, 1264 iron chelated by, 138 no interference with action of anti-HLA-Al antibodies by, 642 polyclonai lgM autoantibody production associated with, 863 Cholesterol elevated serum, as risk factor for cardiovascular disease, 99 Cholinesterase inhibitors, against hypomania, 109 isozymes, quantitative analyses of' 871 Circadian rhythms of core body temperature in depression, 39 Circulatory disease family history of, as risk factor for cardiovascular disease, 99 Clinicai polysomnogram nocturnal, narcolepsy assessed via, 1057 Clomipramine
BIOLPSYCHIATRY 1990;27:1350-1365
1353
against obsessive-compulsive disorder, 95, 319, 1083 against Tourette's syndrome, 95 Clonazepam against postural myoclonus, ! 116 Clonidine against depression, 802-1e, 803-1e (response) against obsessive-compulsive disorder, 1083 against panic disorder, 802-1e, 803-1e (response) Ciozapine in beagles, 1264 CNS. See Central nervous system Cognitive impairment in ~,,.o~xia n~rvosa, 549 in bipolar disorder, midsagittal ~,'ea brain structures and, 1188 in bulimia ncrvosa, 549 in chronic schizophrenia, 150, 377 histidinemia assciated with, 69 vitamin B,2 and folate effect on, 125 Co-morbidity effect of on linkage studies of psychiatric disorders, 241 Competitive protein binding assay plasma co~isol concentrations measured via, 159 Complex partial seizure disorders kindling as model for, 249 (comntent) Computerized tomography (CT) scan basal ganglia mineralization assessed via, i 38 neuro~natomy of brain in schizophrenia assessed via, 61 progressive ventricular enlargement assessed via, 341 sulcal size in neuroleptic-~, duced akathisia assessed via, 466-1e third ventricle assessed via, 265 Continuous Performance Task impaired attention assessed via, 1133 Controlled Substances Act steroids scheduled under, 561-ed Convulsive therapies model for effects of, 76 (comment) Core body temperature in depression, circadian rhythms of, 39 Correspondence Antiseptal autoantibodies in schizophrenia, 681, 681 (response) Basal ganglia calcification in schizophrenia, 682 Clonidine, cortisol, panic disorder, and depression, 802, 803 (response) Dexamethasone suppression test in Brazil, 678 Fluoxetine in refractory depression, 461
1354
BIOLPSYCHIATRY 1990;27:1350-1365
Hirsutism in women with chronic psychiatric illness, 460 Humming, auditory hallucinations, and dystonia, 934 Lorazepam and anticholinergics in tardive akathisia, 463 Melanocyte-stimulating hormone in tardive dyskinesia, 676, 677 (response) Metoprolol versus propranolol, 673 Olfactory functioning in schizophrenia and depression, 457, 458 (response) Panic attacks end multiple sclerosis, 672 Paradoxical mood changes during pharmacotherapy of bipolar patients, 1183 Rapid cycling following antidepressant in an adolescent, 1184 Rhythmic movements of chronic akathisia, 465 Sulcal size and neuroleptic-induced akathisia, 466 L-Tryptophan in neuroleptic-induced akathisia, 671 Verapamil in stuttering, 680 Waking in a lighted room, 372 Cortical atrophy in elderly depressives, prior ECT associated with, 102 Corticosteroids ~uicidality correlated with psychosis induced by, 459-1e Corticosterone CRH-induced release of, 1094 Corticotropin-releasing factor (CRF) antidepressant and anxiolytie drug interaction with, 953 challenge, ACTH secretion in response to in depression, 938 CSF, in nervous and normal pointer dogs, 791 in depression, 938 -reduced anorexia, decrease in, 1094 limbic-hypothalamic overdrive-caused hypersecretion of, 160 Cortisol in bulimia, 1021 circadian rhythm, in eating disorders, 1007 escape, arginine vasopressin role in, 1249 after DST in Parkinson's disease, 581 clonidine effect on, 802-1e, 803-1e (response) plasma concentrations of, 159 postdexamethasone values of, 601 serum, symptom severity in depression and, 311 L-tryptophan effect on values of, 601
Subject Index to Volume 27
twenty-four hour urinary, excretion of in posttraumatic stress disorder, 245 CRF. See Corticotropin-releasing factor CSF. See Cerebrospinal fluid Cycloid illnesses psychosurgery against, 363 Cytogenetic testing for fragile X syndrome, 225 Delta wave analysis sleep-related growth hormone secretion and, 497 Delusions mineral accumulation-induced, 143 Dementia vitamin Bn and folate deficiencies associated with, 125 Depression ACTH in, 930, 938 age-adjusted threshold values for reduced REM latency in, 841 aging and, 311 alcoholism-associated, 31,478 antithyroid antibodies in, 51 arginine vasopressin secretion impaired in, 1249 bulimia nervosa as biological variant of, 454 ~:cll-mcdiatcd immune fu~.-',~ionreduced in, 22 cholinergic REM sleep induction in, 441 circadian typology of, 39 cortical atrophy in, 102 cortisol in, 159, 311,802-1e, 803-1e (response) CRF activity and, 938, 953 decision disorders in, 813 dexamethasone concentrations in, 59, 311,990, 1156, 1249 differential prediction of vegetative and cognitive symptoms in, 3! 1 DST in, 59, 311,990, 1156, 1249 ECT against, 76 (comment), 102, 289 fatigue in, 2-ed folate levels in, ! 25 geriatric onset, sleep disturbances in, 431 growth hormone secretion in, 1065, 1227 HLA antigens in, 664 HPA axis abnormalities in, 601,930, i 156 5-HIAA in, 489 5HT2 receptor changes in, 489 immune function reduced in, 22 inositol-l-phosphatase levels in, before and after lithium treatment, 552 insomnia in~ 431 learned helplessness model of, 546
Subject Index to Volume 27
LHRH in, 1065 limbic seizures and, 249 (coi~ment) multiplicity of episodes in, 115~ olfactory functioning impaired in, 457-1e, 458-1e (response) Parkinson's disease-associated, 581 psychosurgery against, 363 REM latency as diagnostic test for, 990 sensory gating deficit in, 519 TSH in, 472 vasopressin neurophysin in, 1249 ventricle/brain ratio in, 102, 342 Desipramine length of time required for elimination of from system, 657 (comment) Developmental disability fragile X syndrome role in, 223 Dexameth~.sone ACTH suppressed by, 930 free fatty acid levels increased by, 854 insulin levels increased by, 854 plasma, concentrations of, 159 resistance, hypereortisolism in psychiatric disorders and, 937 t.-tryptophan availability reduced by, 854 Dexamethasone snppression test (DST) in Brazil, 678-le in bulimia, 1021 cortisol response to, 601, 1249 depression assessed via, 59, 311,990, 1156, 1249 diagnostic efficacy of plasma and salivary, 897 in nondepressed bulimics, 454 Parkinson's disease and, 58! plasma dexamethasone concentrations and, 159, 592 reserpine-induced nonsuppression in, 546 serial, in psychiatric inpatients, 609 |.-tryptophan response to, 601 vasopressin neurophysin levels after, 1249 Diagnostic Interview Schedule lifetime history of depression determined by, 3 I Diazepam in beagles, 1264 growth hormone secretion and, 702 Diencephalon stimulation of, beneficial effects of ECT and, 1282 Diet in bulimia nervosa, nomdmnergic disturbances and, 4
eiOL PSYCHIATRY 1990;27:1350-1365
1355
Differential reinforcement of response duration in dogs, 1264 Discrimination assessment of, 813 Disso~.ation in multiple personality disorder, 1045 DNA marker studies of affective disorders, 241 Dominant accentuation theory of beneficial effects of ECT, 1282 Dopamine amphetamine effect on wave size mediated by, 184 cistemal CSF and plasma concentrations of, 1179
hypothesis, of schizophrenia, 510, 661, 1023, 103~ Dopamine-beta-hydroxylase in schizophrenia, ! 176 Dopamine D-2 receptor modulatory effect of iron on, 138 Down's syndrome brainstem auditory-evo~'ed response in, with and without sedation, 834 Dreams
involuntary nature of, I 186-ed Drug-free period length of prior to biological evaluation, 657 (comment) DSP-4 neurotoxin selective iesioning of central noradrenergic nerve terminals via, 184 DST. See Dexamethasone suppression test Dynamic single-photon emission computed tomography regional cerebral blood flow in chronic schizophrenics assessed via, 377 Dysthymia sleep patterns in, 649 Dystonia sensory ~cks for relief of, 934-1e ECG. See Electrocardiogram ECT. See Electroconvulsive therapy Edinburgh lp,ventory handedness assessed via, 62 Editorial The black hole of trauma, 469 The concept of the unconscious, i 185 Lithium research: state of the art, ! 279 A national health program for the USA, 123
1356
BIOLPSYCHIATRY
Subject Index to Volume 27
1990;27:1350-1365
Psychoimmunology and cellular nutrition: an alternative hypothesis, 1 Psychotropic drug development: challenge and promise, 1061 Redundant publication, 375 Steroids and ~thecontrolled substance act, 561 The undeveloped countries: biological psychiatry in India, 687 Voiced images, imagined voices, 811 E.~G. See E|ectro~ncephalogram Elderly anemia in, 125 cortical atrophy in depressed, 102 sleep patterns in depressed, 431 vitamin B,2 and folate status in, 125 Electricity in convulsive therapy, 76 (comment) Electrocardiogram (ECG) amytriptyline effects assessed via, 1053 Electroconvulsive therapy (ECT) brain T! levels following, ! 16 free thyroxine index decrease after, 784 -induced seizures, hyperventilation role in prolongation of, 799 mechanisms of action for, 1282 memory impairment induced by, vasopressin alleviation of, 289 mood disorders treated via', 76 (comment) structural brain changes related to, 102 Electroencephalogram (EEG) delta wave activity measured via, 497 ECT mechanisms of action assessed via, 1282 fast frequency activity, in sons of alcoholics, 631 power spectrum profile, in schizophrenia, 1331 sleep recordings, 432, 477,649 waking, quantitative indices for evaluation of in ¢lepression, 757 Electr¢[ytes changes in e;vels of, after lactate infusion, 104 Enalapril against self-induced water itRoxication, 787 {3-Endorphin after DST in Parkinson's disease, t~Sl Epilepsy limbic, kindling model and, 249 (¢'omment) Epinephrine in posttraumatic stres.~ disorder, 2~.5, 1165 Ethanol challenge: plasma GABA-like activity in :esponse to, 617
Event-related brain potential in combat veterans with postuaumatic stress disorder, 419 correlates, of impaired attention, 1103 Excessive daytime sleepiness in narcolepsy, i057 Exercise serum lactate levels during, in anxiety disorder patients, 411 Eye movements as indicator for schizophrenk~, 70, 975 Fatigue depression characterized by, 2-ed Fatty. acids free, dexamethasone effect on levels of, 854 long-chain, immune system cell utilization of, I -ed Fenfluramine prolactin response to, ! 143 Finger movement abnormal, neuroleptic-associated, 1116 Fluorescent polarization immunoassay plasma cortisol concentrations measured via, 159 Fluoxetine against obsessive-compulsive disorder, 319, 1083 against refractory depressiun, 461-1e Flupenthixoi against schizophrenia, | " "~3 Flurothyl in convulsive therapy, 76 (comm:nt) Fluvoxamine against obsessive-compulsive disorder, 319, 1083 Folate serum, in geriatric psychiatric patients, 125 Follicle stimulating hormone (FSH) in bulimia, 1021 Forskolin adenylate cyclase activity stimulated by, 735 Fragile X syndrome specific patterns of psychiatric d.lsturbance caused by, 223 Frontal lobes of psychiatric patients, brain Ti in, 116 in schizophrenia, abnormalities in, 1038 GABA. See Gamma-aminebutyric acid Galanin CSF levels of, 923
Subject Index to Volume 27
Gambling pathological, CSF galanin levels in, 923 Gamma-aminobutyric acid (GABA) benzodiazepine effect on inhibitory neuronal properties of, 702 -benzodiazepine receptor mechanism, CRF interaction with, 953 -like activity, in response to ethanol challenge, 617 uptake sites, hippocarnpal in schizophrenia, 1038 Gender anxiety ~isorders and, cardiovascular disease associated with, CNS serotonergic responsivity and, 1143 electrodermal activity in schi:opluenia and, 328 fragile X syndrome-caused psychiat,-ic disturbances specific to, 223 Gene penc'rance effect of on linkage studies of psychiatric disorders, 241 Globus pallidus iron deposition in, 143 neuronal cell loss in ..rid m~:neralization of in schizophrenia, 138 Glur.ocorticoid feedback inhibition dexamethasone resistance to, 937 Glucose immune system cell utilization of, I-ed infusion, GHRH-induc~d GH release not suppressed by in anorexia nervosa, 215 Glucose-6-phosphate dehydrogenase linkage ansiysi~ in bipolar family and, 241 Glutamine immune sy.+~m cell utiiization of, l-ed Glutaminolysis as dynamic buffer, 1-ed Growth hormone (GH) in bulimia, 1021 circadian rhythm, in eating disorders, 1007 cionidine effect on levels of, 1083 in dep,,ression, 1227, 1065 diazepam effect on levels of, 702 exaggerated response of to GHRH ~n anore×ia nervosa, 215 respox~se to TRh in panic disorder, 1227 secretion, at sh:ep onset, 497 Growti3 hormone-releasing hormone (GHRH) exaggerated GH response to in anorexia nervosa,
Hallucination
BIOLPSYCHIATRY 1990;27:1350-1365
1357
mine~'al accumui,qtion-induced, 143 Halope~,~ol amphetamine inhibitiott of sensory gating reversed by, 183 in beagles, 1264 blink rate response to, 113 plasma c~iolinestemse isozyme levels affected by, 871 against schizophrenia, 510 -stimulate~ pt~!actin in schizophrenia, 1203 t~dlve dyskinesia caused by, 139 in third cerebral ventricle assessment, 205 against Tourette's syndrome, 95 Hamilton Depression Scale serum folate levels in major ~lepression correlated with scores on, 126 Heart rate in anxiety disorders, TRH effect on, 781 clonidine effect on levels of, 1083 in posttraumatic stress d~sorder, 1165 Hemispheric dysfunctions resolution of, beneficial effects of ECT and, 1282 Herpes simplex virus latent, lithium-induced inhibition of reactivation of, 447 Hexafluorodiethylether in convulsive therapy, 76 (comment) 5-1-11AA. See 5-Hydroxyindole acetic acid Hibernation changes in energy balance in, behavioral abnormalities in depression compared to, +~ Hippocampus auditory sensory gating model involving neurons in, 183 GABA uptake sites in, in schizoph'enia, 1038 lithium effect on synapfic transmissions in CAI aeurones in, 174 Hirsutism female, in chronic psychiatric illness, 4fi0-1e Histidinemia heterozygosity for, in schizophrenia, 69 HLA aatigens in depression and hypersomnia, 664 HLA-AI alloantibodies directed against, no evidence of chlorpromazine interference with action of, 642 Holter monitoring ECG effects of amitriptyline assessed via, i053 Homovanillic acid
1358
Subject Index to Volume 27
BIOL PSYCHIATRY 1q90:27:!350--1365
CSF levels of, 280, g91, 1179 plasma concentrations of, ! 179 in schizophrenics, after haloperidol treatment, 510 HPA axis activity, in nervous and normal pointer dogs, 79! in bulimia, 1021 in depression, 601,930, 1156 disirdaibited corfisol secretion due t-~ abnormalities in, 159 Humming auditory hallucinations reduced via, 934-1e 5-Hydroxyindole acetic acid (5-HIAA) CSF concentrations of, 891,926, 1179 in depression, 31 !, 489 in neuroleptic malignant syndrome, 280 in obsessive-compulsive disorder, 95, 319 plasma concentrations of, 891,926, ! 179 among suicidally depressed patients, 459-1e in Tourette's syndrome, 95 5-Hydro.~ytryptamine receptor changes, in major depression, 489 Hyperactivity fragile X syndrome role in, 223 Hypercertise!!sm neural bases of, 937 Hyperglycemia in acute phase anorexia ncrvosa, inhibitory action of on GHRH-induced GH release lost in, 215 concmrent with hyperventilation, serum lactate rise induced by, 411 Hypersomnia in affective disorders, 372-1e HLA antigens in, 664 Hypertension as risk f ~ o r for e.~rdio,~asculardisease, 99 Hyperthyroidism thyroid autoimmuni~y as c~,~se of, 51 Hyperventilatio, during ECT. seizure., length and. 790 voluntary, during tatw ,,enic hyperglycemia to induce panic attacks, 41 | Hypoadrenocortism neural bases of, 937 Hypocapnia seizures and, 799 Hypo"ronta!ity .~ in thronic schizophrenia, 377 Hypothalamus
decreased noradrenergic turnover in, food reduction and, 5 paravemricular nuclei of, galanin-like immunoreactivity in, 923 Hypothyroidism subclinical, as risk factor for affective disorder, 52 thyroid autoimmunity as cause of, 51 Ideas of influence mineral accumuiation-iaduced, i43 Ideas of reference mineral accumulation-induced, 143 antibodies, in mental disorders, 747, 863 IgM antibodies, in mental disorders, 747 neuroleptic-associated, prevalence of, 863 Imipramine against atypicel depression, 442 CRF interaction with, 953 paradoxical mood changes upon withdrawal of, I 183-1e
tritiated, binding of to piare|ets L-,.obsessivecompulsive disorder, 319 ~mmune function ~,mpaired, psychological stress and, l-ed reduced cell-mediated, in depression and stress, 22 India biological psychiatry in, 687-ed Indoklon in convulsive therapy, 76 (comment) Inositol- l-phosphatase red blood cell, lithium inhibition of, 532 Insomnia depression-associated, 431 Insulin dexamethasone effect on levels of, 854 • ,.vv,u,,t~,~
/i~O'¢¢,ili~iitS
abnormal, in chronic schizoph~.ia, 150 Iron
role of in schizophrenia, 1~8, 143 Kindling phenomenon beneficial efft~ts of ECT and, 1282 limbic epilepsy and, 249 (comment)
-induced panic attacks, hyperventi~atic,n role in, 411
Subject Index to Volume 27
infusion, CNS effects of, 193 panic attacks induced by, 104 Language disorder fragile X syndrome role in, 224 Latency reduction visual evoked potential, in schizophrenia, 400 Lateral ventricular enlargement in schizophrenia, 61, 102, 1331 Learned helplessness model of depression, DST nonsuppression in, 546 Leprosy lepromatous, antibodies in, 863 l_euco~omy .,~,. against psychiatric illness, 363 Leukoaraiosis in asy~aptomatic adult offspring of Alzheimer's disease patients, 1244 LH. See Luteiuizing hormone LHRH. See Luteinizing hormone-releasing hormone Light treatment with bright, effect of on core body temperature in seasonal affective disorder, 39 Limbic encephalitis paraneoplastic, 529 Limbic system schizophrenia and, 329 Linkage studies of psychiatric disorders, effects of co-morbidity and gene penetrance on, 241 Lithium auditory-evoked potentials affected by, 555 brain TI levels after treatment with, 116 effect of on synaptic transmissions, in rat hippocampus CAI neuron,s, 174 exposure to, antithyroid antibody presence unrelated to, 51 in healthy volunteers, 711 HLA-A3 ~sociated wi!b negative ~_~-se_*_~. inhibiti~m, of myo-inositol-l-phosphatase, 552 ion, re0uced cell membrane affinity for, 795 ~ against latent herpes simplex virus, 447 manic state induced by, 1184-Ie paradoxical mood changes upoa withdrawal of, 1183-Ie prophylaxis, folate supplementation of, 126 r~seareh, 1279-ed I..OATS computer analysis system CT s¢~l films analyzed via, 138. 143
BIOLPSYCHIATRY 1990;27:1350-1365
1359
Locus coeruleus firing of, sweet water consumption role in ~duced, 5 galanin-like immunoreactivily in, 923 Lorazepam against tardive akathisia, 463-1e Lo~.ver-bandpass filter frequency P3 latency and, 667 Lupus anticoagulant antibodies neuroleptic-associated, 863 Luria*Nebraska Batter3, neurological impairment in chronic schizop~enia assessed via, 377 Luteinizing hormone (LH) in bulimia, 1021 Luteinizing hormone releasing hormone (LHRH) growth hormone response m in endogenous depression, 1065 Lymphocytes nutrition of, psycheimmunology and, l-ed responses of to mitogenic stimulation, reduction of due to depression and stress, 22 Macrophages nutrition of, psychoimmunology and, l-ed Magnetic resonance imaging (MRI) Alzheimer's disease-~elated whtte matter changeb assessed via, 1244 brain TI measured via, 116 of cerebral structares, in bipolar disorder, 1188 controlled multiplanar, schizophrenia assessed via, 61 midbrain ventral tegmentum assessed via, 661 serial, ECT-t~eated depressives assessed via, 102 ~emperal lobe abnormalities in panic disorder assesse~ v~a, 3 ~ Malnutrition schizophrenia risk and, 328 Mania ar~in~e vasop~ssin function in, !249 decision disorders in, 813 lithium-induced, 1184-~e physostigmi~ ~g~nst, 109 psychosurgery against, 363 R$ 86 against, 109 sensory gating deficit in, 519 Manic depressive disorder circadian temperature rhythms ie, 40 inositol-l-pbosphatase leveis in, bef¢,re and after lithium treatment, 552 psychosurgery against, 363
1360
BIOLPSYCHIATRY
Subject Index to Volume 27
1990;27:1350- ! 365
MAO. See Monoancline oxidase Mean eye scanning length in schizophreuia, 975 Meige's syndrome sensory tricks for relief of, 934-1e Melanocyte-stimulating hormone (MSH) plasma, in tardive dyskinesia, 676-1e, 677-1e (response) Melatonin circadian rhythm, in eating disorders, 1007 Memory characterization of, 1186-ed vasopressin role in, 289 Menses in bulimia nervosa, noradrenergic disturbances and, 4 Mental impairment histidiaemia associated with, 69 mineral accumulation-induced, 143 Me.~tal retardatic,u fr~,gile X syndrome role i~, 223 self-injurious behavior hi, haltrexone against, 741 Methylphenidate blink rate response to, I 1~ Metoprolol against neuroleptic-induced ~athisia, 673-1e Metrazol in convulsive therapy, 76 (comm:nt) MHPG age-related increase of, in detoxifieo alcoholics, 626 cisternal CSF and plasma concentrations of, ! 179 clonidine effect ~n, 1083 CSF levels of, in neuroleptie malignant syndrome, 280 plasma levels of in schizophrenics, after haloperidol treatment, 510 sensory gating deficit associ..~.te4w;.th ptasma-free levels of, 519 Midbrain tegmentum schizophrenic syndrome associated with lesion in, 661 Mini-Mental State scores in vitamin-deficient geriatric psychiatric pat~euts, 125 Mouoamine oxidase (MAO) inhibito~s, p~adoxical mood changes upon with,Irawe! of, 1133..le platelet, in alcoholism subtL~es, 91 I Monoamit~es
CSF, metabolism of in neuroleptic malignant syndrome, 280 Mononucleosis antibodies in, 863 Motor behavior stereotypic, fragile X syndrome role in, 223 Motor dis~rbances mineral accumulation-induced, 143 MSH. See Melanocyte-sfimulating hormone Multidimensional Personality Questionnaire personality resemblance in familial alcoholism assessed via, 1305 Multiple persoaality disorder treatment of, 1045 Multiple sclerosis panic attacks in, 672-1e Multiple Sleep Latency Test narcolepsy assessed via, 1057 Myoclonus postural, neuroleptic-associated, 1116 Myositis antibodies in, 863 N40 wave auditory sensory gating and, 183 N I 0 0 latencies visual evoked potential, in schizophrenia, 401 Naloxone against self-injurious behavior, 741 Naltrexone aversiv¢ response ill drug-naive rats induced by, 543 against self-injurious beltavior, 741 Narcolepsy assessment of, 1057 National health program for the United States. 123-ed Natural killer cells cytotoxicity of, reduction of due to depression Neoplastic cells nutrition of, psychoimmunology and, l-ed Neuroleptic malignant syndrome CSF monoamine metabolism in, 280 Ne,urological i,,lpairment in chronic schizophrenia, !150, 377 Neurotransmitters synthesis of, vitamin ~absorption-associated inhibition of, 126 Neutron activation analysis aluminum tissue concentrations assessed via, 884 New Haven SchizopLrenic Scale
Subject Index to Volume 27
scores on in study of third ventricle enlargement in psychotics, 205 Nimodipine against Alzheimer's a:'~ease, 1133 Nipecotic acid radiolabeled, as marke~"of GABAergic neurons, 1038 Non-rapid eye movement (NREM) sleep patterns, during alcohe~ withdrawal, 477 Norepinephrine amphetamine blockade of paired stimulus suppression mediated by, 184 cisternal CSF and plasma concentrations of, 1179
in neuroleptic malignant syndrome, 280 neurons, galanin as cotransmitter with, 923 plasma, during bingeing and vomiting, 4 in posttraumatit; sh~ess dise,rder, 1 ! 66 system, in schizophrenic F,iychopatho!ogy, 510 twenty-four hour urinary, excretion of in posttraumatic stress disorder, 245 NREM. See Non-rapid eye movement Obesity hormonal circadian rhythms in. 1007 Obsessive-compulsive disorder a2-adrenoreceptor status in, 1083 clomipramine against, 95 tritiated imipramine binding in, 319 Obstetrical complications schizophrenia ~isk and, 328 Olfactory functioning impaired, in schizoi~ertia and depression, 457-1e, 458-1e (rcspons::) Opioid antagonists receptor-mediated aversive effects of, 543 Overuse syndrome immunopsychological role in-ed, 2 P3 latency i~? schi:zophrenia, 667 P50 auditory-evoked potential sensory gating and, i84, 519 suppression, in schizop~'m~nia, !2i6 P200 latency visual evoked potential, in schizophrenia-. 400 Palladum internum iron content of in schizophrenia, 144 Panic attacks 13¢~ lactate-induced, 104, ,n., in multiple sclerosis, 672-1e Panic disorder
r :OLPSYCHIATRY 1990 27: i 350-1365
1361
five percent carbon dioxide ~hallenge-induced response similar to, 689 growth hormone response to TRH in, 1227 hyperventilation-induced inct.~ase in serum lactate during, 41 ! serum cholesterol levels in, 9~ skin conductance habituation i:t, 1231 tempor~! lobe abnormalities in, 304 TRH effect on blood pressure and heart rate Lq, 7gl Paranoia frontal cerebral flow deficits in, 377 Parkinsonism neuroleptic~a~sociated, 1 ! 16 Parkinson's disease ~CTH in after DST, 5~1 cortisol in after DST, 581 I~-endorphin in after DST, 581 PEG. See Pneumoencephalography Penlobarbital CRF interaction with, 953 Pentylenetetrazoi in convulsive therapy, 76 (comment) Perseveration fragile X syndrome role in, 223 Personality resemblance in relatives of male alc~.holics, i305 Phenelzine against atypical depression, 442 paradox;eal mood changes upon withdrawal of, ! 183-1e
Pi~enothiazines polyclonal IgM elevation associated with, 863 l~.~enytoin hair growt~h ~ndueed by, 460-1e Phobia TRH effect on blood pressure and heart rate in, 781 Phosphate plasma concentrations of, la4"~ate-induced punic mtacks and, 104 Phosphatidylino~sitol reduced syn~,esis of after lithk'm ra~atmet t, 552 Ph~spholipa~e C in posttranmatic stress disorder, 735 Physical acfiviq¢ noradrenergi¢ dist~rhances and, 4 Physostigmine ~ainst hypo~rmnia, 109 Filo~~vine h'Lh_b~,m~coadministration, limbic seizures i~duced by, 552
1362
tool PSYCHIATRY
Subject Index to Volume 27
199~%27:1350-1365
Pimozide against Tourette's syndrome, 95 Pneumoencephalography (PEG) progressive ventricular enlargement in chronic schizophrenia assessed via, 341 Postmortem studies iron deposition assesses via. 138. i43 Posttraumatic stress disorder autonomic responses to stress in. 1165 cortisol and catecholamine excretion in. 245 domination of though*~sby traumatic events in. 469-ed event-related brain potentials in. 419 I>2 reduction in. 419 phospholipase C activity in. 735 platelet adenylate cyclase activity in. 735 Prenatal complications schizophrenia risk and. 328 Procyclidine against tardive akathisia. 463-1e Prolactin basal and haioperidol-stimulaicd, in schizophrenL~. 1203 in bulimia. 1021 eireadi~.n rhythm, in e.ating d~st.rders. 1007 fenfluraznine-induced. ! 143 response of to TRH in a~eoholics. 31 Pra0ranolol bias deficit of expressior~ modeled by. 813 against neuroleptic-indu:ed akathisia. 673-1e Prostat..alndin E~ adenylate cyclase activity stimulated by. 735 Proton longit,dl ,al relaxation time (1"1) brain. MRI u:easurement of. ! 16 Pseudocholineslerase levels, quantitative analysis of. 871 Psychoimmunology brain involvement in immune system and. l-ed Psycho-G:ganie syndrome as accompanimem of open leucotomy. 363 Psychopathology in chronic schizophrenia. 150 esychosi~ captopdl-induccd, 968 cerebral third ventricle enlargement in, 2(~5 circular, psychosurgery against, 363 corticosteroid-indu¢,~d, suicidality in, 459-Ie epileptic, 7:49 (comment) methamph~;tamine, eye movements in, 975 mineral aeculnulation-induced, 143 organic, low vitamin B j2 levels associs~=d with, i25
visu~d evoked potential correlates of clinical symptomatology in, 400 Psychosurgery indications for, 363 Purine nucleotide synthesis pathway for, precise regulation of, I-ed Pyriraidine nucleotide synthesis pathway for, precise regulation of, l-ed Quantitative slab gel electrophoresis plasma ~.holinesterase isozyme ievels assessed via, 871 RA24 ambulatory rest-activity monitor circadian rest-activity rhythm alte.r~tions assessed via, 563 Radioimmunoassay plasma dexamethasone concentrations measured via, 159 Rapid eye movement (REM) latency, 649, 841,990 in narcolepsy, 1057 patterns, in geriatric depressed p~fients, 431 sleep patterns, during alcohol withdrawal, 477 Receiving operator characteristic analysis REM latency and, 841,990 Red blt~l cells inositol-l-phosphatase in, lithium inhibitio~ of, 552 Reserpine DST nonsuppression induced by, 546 Response bias assessment of, 813 Response Search Score eye movements scored via, 975 Rest-activity rhythm circadian, alterations in, 563 Restraint stress -induced ~,orexia, decrease in, 1094 Rheu~natoid arthritis antibodies in, 863 Rheumatoid factor antibodies, in chronic mental disorders, 747 neuroleptic-associated, pr~v-al~,lccof, 863 Rituals compulsive, clomipramine against, 95 RS 86 against Alzheimer's disease, 109 as specific muscarinic agonist, i~ manic disorde[, 109 Saline
Subject Index to Volume 27
infusion, GHRH-induced GH release stimulated b.'., in anorexia nervosa, 2!5 Saliva DST, 897 ~chizoaffective disorder ar,~:.thyroid antibodies in, 51 ECT mechanisms of action in, 12~2 Schizophrenia abnormal voluntary movements in, 150 anti-HLA-Al antisera in, 642 antinuclear antibodies in, 747 antiseptal autoantibodies in, 681-1e, 681-1e (response) ~ttention deficits in, 1103 auditory-evnked response in, 1216 basal ganglia mineralization in, 138, 143, 682-1e blink rate in, 113, 1197 cerebral third ventricle assessment in, 205 chronic, abnormal involu~.tary movements in, 150 CNS lactate levels in, 194 CNS structural characteristics in, 1331 cognitive impairment in, 150, 377 convulsive therapy against, 76 (comment) diminished evoked response to repeated auditory stimuli absent in, 183 dopamine-beta-hydroxylase in, ! 176 dopan:ine hypothesis of, 510, 661, 1023, 1038 ECT mechanisms of action in, 1282 LEG power spectrum pronle in, 1331 ele~trodermal activity correlated to season of ~.~th in, 328 event-related potential correlates of impaired attentio~ in, 1103 eye movements in, 70, 975 haloperidol agai~t, 113 hippocampal GABA uptake sites in, 1038 histidinemia associated with, 69 hypofrontality and cognitive i.,np;ah~nent in, 377 involuntary ~.,~vements in, 150 lateral ventricular enlargement in, 61,102, 1331 left hemisphere overactivation in, 378 limbic system and, 329 neurological impairment in, 150, 377 neuropathology of, 353 olfactory functio_,,.in~impaired in, 457-~,~, 458-1e (response) P3 latencies in, 667 PSO potential in, 1216 p!asma catecholamine metabolites in, 510 polydypsia in, 787 positive/negative symptom dichotomy in, 1323
BIOL PSYCHIATRY ! 990;27:1350- ! 365
1363
postural myoclonus in, neuroleptic-assoeiated, 1116 progressive ventricuiar enlargement in, 341 prolactin levels in, 1203 psychopathology of, 150 sensory gating deficit in, 519 sensory trick phenomena in, 934-1e in siblings, 61 [3H]-spiperone binding to intact lymphocytes as biological marker for, 1327 suicidality in, CSF 5-HIAA levels correlated with, 926 temporal lobe abnormalities in, 61, 1038 two-subtype concept of, 510 urinary chromatographic analysis in, 1127 ventricle/brain rat~o in, 61 visual evoked potential and, 490 Scleroderma antibodies in, 863 Season of birth, electrode~mal unresponsiveness in schizophrenia correlated too 328 Seasonal affective disorder core body temperature in, light treatment effec~ on, 39 Sed2tio~ effect of on brainstem auditory-evoked response, 834 Seizures during EL'T, prolongation of by hyperventilation, 799 Self-injurious behavior fragile X syndrome role and, 223 in mental retardation, naltrexone against, 741 Sensitization theory of beneficial effects of ECT, 1282 Sensory gating auditory, rat hippocampal neuron model of, 183 deficits, 519, 1216 Sensory trick phenomena dystonia relieved via, 934-1e Serotonin hypothesis, of obsessive-compulsive disorder, 319, 1083 synthesis of, vitamin malab~tion-assecia~ed inhibition of, 126 Siblings schizophrenic, bilateral reduction in temporal lobe area in, 61 Signal detectio~ theory. response bias assessed via, 813 Skeletal muscle
1364
BIOLPSYCHIATRY
Subject Index to Volume 27
1990~27:1350-I365
role of in psychological stress, brain and immune system interaction and, l-ed Skin conductance habituation, in panic disorder, 1231 Sleep excessive daytime, HLA :ntigens in, 664 in dysthymic patients, 649 in geriatric depressed population, 431 narcoleptic, 1057 in nondepressed bulirmcs, 454 onset, growth hormone secretion during, 497 during withdrawal from pure primary alcoholism, 477 Smell identification test olfactory functioning in schizophrenia and depression assessed via, 457-1e Smoking reduction in natural killer cell cytotoxicity not associated with, 22 as risk factor for cardiovascular disease, 99 Smooth pursuit eye movement evaluation in schizophrenia, 70 Sobriety dun~tion of correlated with sleep patterns. 477 Sodium b~.'lance, noradrenergic function 8nd, 5 Sodium la .*~te infusion, pamc attacks precipitated by, 104 Speech impairments histidinemia associated with, 69 ['~H]-Spipemne binding, to intact peripheral blood lymphocytes, 1327 Starvation intermittent, impaired cognitive f~nction a,~d, 549 Steroids under Controlled Substances Act, 561-~J against ECT-iuduced memory impairment, 289 Stress autenomic responses to, in posttraumatic stress disorder, 1165 chronic, physiological responses in, 22 hirsuti~m tnduced by emotional, 460-1e -induced ~norexia, I094 life, reduced celt-mediated immune function in, 22 psychological impaired immune function and. l-ed
S~ttering verapar~il in, 6~0-1e Subaffecti,~edysthymic disorder sleep patterns in, 649
Substance abuse in monozygotic twins, heritability of, 1293 Substantia nigra iron pigment deposition in, 139, 143 Suicidality anxiety disorders and, 99 CRF activity and, 95¢ CSF 5-HIAA levels and, 926 serotonergic function and, 926 Suprachiasmatic nucleus morphological changes in, aging and, 563 Sympathetic nervous system activation of by bingeing and vomiting, 4 Systemic lupus erythematosus antibodies in, 863 TI. See Proton longitudinal relaxation time T3. See Triiodothymnine T4. See Thyroxine Tardive dyskinesia haloperidol overdose-indu,.ed, iron pigment deposition in, !39 neuroleptic-asscciated, I 116 plasma MSH in, 676-1e, 677-1e (response) Temperature ambient, schizophrenia risk and, 328 Temporal lobes in epilepsy, 10~5 in panic disorder, 304 of psychiatric patients, brain TI in, 116 in schizophrenia, 61, 1038 Tension predisposing to alcoholism, plasma GABA-like activity as biological marker for, 617 Thioridazine in beagles, 1264 birsutism induced by, 460-Ie Third ventricle cerebral, enlargement of in psychotics, 205 Thyroiditis autoimmune, psychiatric effcct~ of, 51 Thyrotropin (TSH) response to TRH, 31,472, 905, 1021 serum levels, in endogenous depression, 472 Thyrotropin-releasing bormone (TRH) blood pressure and, 781 growth hormone r~ ponse to, 1065, 1227 heart rate and, 781 prolactin response to, 3 ! TSH response to, 31,472, 905~ I ~ 1 Ti~yruxine (T4) free, POst-ECT fall in, 784 serum levels, in endogenous depression, 472
Subject Index to Volume 27
Tics multiple, clomipramine agaimL 95 Tourette's syndrome elomipramiiie against, 95 Trauma memow-evoking cues of, in posttraumade stress ~sorder, 1165 TRH. See Thyrotropin-releasing honr.one Tricvclic antidepressants ca'.~liotoxicity of, 1(~53 against obses~ive-compulsive disorder, 95 paradoxical mood changes upon withdrawal of, 1183-1e
rapid cyclh~g induce~ by. 1184-1e against Tourette's syndrome. 95 Triiodothyronine (T3) levels, in endogenous depression. 472 Trimipramine rapid cycling induced by. 1184-1c Tritium film autoradiography 5HT, recept¢, studied via~ 489 L-Tryptophan availability of. in depressed females. 601 dexamethasone effect on availability of, 854 membrane transport, in erythrocytes. 723 in neuroleptic-induced akathisia. 67 l-le prolactin response to. 1143 TSH, See Thyrotropin Tumor~ solid, antibodies in, 863 Twins monozygotic, heritability of substance abuse and antisocial behavior in, 1293 Two-subtype concept of schizophrenia, 510 Type A behavior as risk factor for cardiovascular disease, 99 L-Tyro,sine membrane transport, in erythrocytes, 723 Unconscious concept of 1185-ed Uric acid CSF concentr,,~ion gradients of, 891 Urine chromatographic an.:lysis, in schizophrenia, !12'/ ~'~sopressin ECT*induced memory impairment relieved by, 289 neurophysin, in depression, 1249
BIOL PSYCHIATRY 1990;27: ! 350-1365
1365
Venlricle/brain ratio in depression, 102, 342 in schizophrenia, 61 Ventricles progressive enlargement of in schizophrenia, 341 size of, blink rate and, 113 Verapamil against stuttering, 680-1e Vigilance performance rolatkJ~,ship of to biological adaptation to starvation, 549 Violence episodic, in multiple personality disorder, 1045 Viral infections schizophrenia risk and, 328 Visual evoked lx,tentials flash, as correlates of clinical symptomatology in schizophrenia, 400 Vitamin BI2 serum, in geriatric psychiatric patients, 125 Vitamin deficiencies schizop~reni~ risk and, 328 Voluntary movements abnormal, in chronic schizophrenia, 150 Vomiting norepinephrine levels and, 4 WAIS IQ test in schizophret~i~ 70 Water intoxication self-induced, management of, 787 Wechsler Memory Test serum folate levels in major depression correlated with scores on, 126 Weight noradrenergic disturbances and, 4 White matter changes, in Alzheimer's disease, 1244 Wisconsin Card Sorting Test neurological impairment in chronic schizop~hrenia assessed via, 377 X chromosome human, MAO stmctual ~enes assigned to, 911 -linked mental retardation syndrome, fragile X syndrome originally ~escribed as, 223 Yohimbine against obsess~ve-compulsive disorder, i084 Zimelidine anti-obsessional properties of, 319